ILF3 divergent transcript (ILF3-DT)

ILF3 divergent transcript (ILF3-DT), also known as ILF3-AS1 and other variants, is a long non-coding RNA (lncRNA) located on chromosome 19p13.2, which does not encode a protein[1][4]. ILF3-DT functions mainly in the regulation of gene expression, frequently by interacting with microRNAs and influencing transcriptional and post-transcriptional regulatory networks[1]. It has been shown to display tumor-suppressive properties in cervical cancer, inhibiting cell proliferation and migration while promoting apoptosis through the inhibition of epithelial-mesenchymal transition[1]. Conversely, in other cancer contexts (e.g., melanoma, osteosarcoma), its upregulation is associated with enhanced tumorigenicity, possibly by negative regulation of specific microRNAs[1]. Thus, ILF3-DT's roles are context-dependent, and it is being studied primarily as a potential prognostic biomarker or contributor to cancer pathogenesis rather than as a direct therapeutic target[1][4]. ILF3-DT is distinct from the protein-coding gene ILF3, which encodes a double-stranded RNA-binding protein involved in RNA processing and antiviral responses; ILF3-DT is non-coding and acts through RNA-mediated regulatory mechanisms[1][4][5]. No small-molecule drugs or targeted therapies are currently known to interact directly with ILF3-DT, and it is not conventionally classified as a therapeutic target such as a receptor, enzyme, transporter, or transcription factor. Its primary significance lies in its role in cancer biology and biomarker research[1][4].

Other names

ILF3-AS1CTC-539A10.4ILF3 antisense RNA 1 (head to head)ILF3 antisense RNA 1 (non-protein coding)ILF3-DT